# AGRICULTURAL AND FOOD CHEMISTRY

Article

# Identification of the Bioavailable Peptidome of Chia Protein Hydrolysate and the In Silico Evaluation of Its Antioxidant and ACE Inhibitory Potential

Alvaro Villanueva, Fernando Rivero-Pino, Maria E. Martin, Teresa Gonzalez-de la Rosa, Sergio Montserrat-de la Paz,\* and Maria C. Millan-Linares

| Cite This: https://doi.org/10.1021/acs.jafc.3c05331 |                    |  | Read Online               |                        |
|---|--------------------|--|---------------------------|------------------------|
| ACCESS  | III Metrics & More |  | E Article Recommendations | Supporting Information |

**ABSTRACT:** The incorporation of novel, functional, and sustainable foods in human diets is increasing because of their beneficial effects and environmental-friendly nature. Chia (*Salvia hispanica* L.) has proved to be a suitable source of bioactive peptides via enzymatic hydrolysis. These peptides could be responsible for modulating several physiological processes if able to reach the target organ. The bioavailable peptides contained in a hydrolysate obtained with Alcalase, as functional foods, were identified using a transwell system with Caco-2 cell culture as the absorption model. Furthermore, 20 unique peptides with a molecular weight lower than 1000 Da and the higher statistical significance of the peptide-precursor spectrum match ( $-10 \log P$ ) were assessed by in silico tools to suggest which peptides could be those exerting the demonstrated bioactivity. From the characterized peptides, considering the molecular features and the results obtained, the peptides AGDAHWTY, VDAHPIKAM, PNYHPNPR, and ALPPGAVHW are anticipated to be contributing to the antioxidant and/or ACE inhibitor activity of the chia protein hydrolysates.

KEYWORDS: ACE, bioactive peptides, DPPH, identification, protease, subtilisin

### 1. INTRODUCTION

Seeds of chia (*Salvia hispanica* L.) are considered a nutritionally interesting food based on its content of fiber (ranging from 30 to 34%), oil (25–40%), and high-quality protein (18–24%). It was certified as a safe and novel food by the Food and Drug Administration (USA) in 2005, and in Europe, it was authorized to be marketed in 2009.<sup>1,2</sup> Focusing on the protein fraction, the content is higher than in common food products like wheat, oats or rice, and comparable to other seeds used to produce protein isolates like hemp, peas, and chickpeas.<sup>3</sup> The protein fraction, as an isolate, can be used as a source of peptides by enzymatic hydrolysis.

Research on bioactive peptides derived from chia demonstrate antibacterial,<sup>4</sup> angiotensin converting enzyme (ACE) inhibitors,<sup>5</sup> and antioxidant<sup>6</sup> properties in vitro, among others. In addition, analysis employing cell culture<sup>2</sup> or rats<sup>7</sup> increase the evidence that these peptides can modulate the physiological status of human beings. At a nutritional level, protein cleavage into low molecular weight peptides improves their digestibility and can lead to loss of antigenicity, decreasing the immunoreactivity of the native protein.<sup>8</sup> The enzymatic hydrolysis does not imply loss of nutritional value from the amino acids based on the mild reaction conditions.

The consumption of plant-based peptides, such as chia, is aligned with the Sustainable Development Goals (SDGs), such as "Good health and well-being", "Responsible consumption and production", and "Climate action", based on the environmental-friendly character of plant crop production, and the health benefits associated with these products.<sup>9</sup> However, there is little research concerning the bioavailability of peptides,<sup>10</sup> and consequently, it is difficult to attribute actual health-promoting effects to these peptides. Their functionality is linked to their stability, which is dependent on the sequence. Their susceptibility to be degraded by gastrointestinal enzymes and their capacity or not to cross the intestinal barrier hinder their use as functional ingredient. In a mixture of peptides obtained by enzymatic hydrolysis, some of them are bioactive, and others are not. The comprehensive identification and characterization of the bioavailable peptides, that can be involved in controlling a disease, allows the producer to assert that the product might exert health-promoting properties. Protein hydrolysates are composed of a variety of molecules (amino acids, low molecular weight peptides or oligopeptides, proteins, as well as nonproteinaceous material) with very similar structures, impeding sometimes a full identification of the peptides and proteins mixture. To this regard, the development of bioinformatics tools, including in silico analysis can help to overcome this limitation, like Uniprot (KB) or Protein Data Bank for the acquisition of the amino acid sequences of proteins, and BIOPEP "Enzyme action" or ExPasy Peptide Cutter for in silico protein digestion. Currently, several studies are combining in vitro and in silico

Received: July 31, 2023 Revised: January 17, 2024 Accepted: January 23, 2024



analyses to fully explore the potential of bioactive peptides as functional ingredients.<sup>11,12</sup>

Based on literature published, we hypothesized that peptides below <1000 Da would be bioavailable and bioactive, depending on their sequences. Many reports suggest that peptides obtained by Alcalase are bioavailable, but scarce information, to the author's knowledge, has been published in relation to peptidome characterization subjected to cell culture-absorption conditions. Focusing on the antioxidant and ACE inhibitors character that peptides can have, especially from chia, there is still several gaps that requires research in the upcoming years.<sup>13,14</sup> The aim of this study was to evaluate the bioavailable peptidome of a chia protein hydrolysate obtained with Alcalase. Peptides were identified from the original hydrolysate and from the fraction collected after subjecting the hydrolysate to Caco-2 cells in a transwell model. The peptides with a molecular weight <1000 Da with higher  $-10 \log P$  value (corresponding to statistical significance of the peptideprecursor spectrum match) were subjected to several in silico analysis to characterize their bioactivity, as antioxidants and ACE inhibitors agents.

#### 2. MATERIALS AND METHODS

**2.1. Chemicals and Samples.** *S. hispanica* L. seeds were supplied by the Autonomous University of Nuevo Leon (Monterey, Mexico), from which the protein was isolated, as described previously<sup>3</sup> The enzyme used was Alcalase 2.4 L, which was supplied by Novozymes (Novozymes, Bagsvaerd, Denmark). The rest of the chemicals (of analytical grade) were bought from Sigma Chemical Co. (St. Louis, MO, USA) and Merk (Merck, Darmstadt, Germany).

**2.2. Hydrolysis of Chia Protein Concentrate.** The chia protein concentrate (CPC), with a protein content of 82.85%, was dissolved at 7.5% w/v in distilled water to be hydrolyzed employing Alcalase as the catalyst. The enzyme-to-substrate ratio was 0.3 AU/g protein. One Anson activity unit (AU) is defined as the amount of enzyme that will release 1.0  $\mu$ mol L-tyrosine from hemoglobin per min at 25 °C and pH 7.5. Temperature and pH were maintained at 50 and 8, respectively. The enzymatic reactions were carried out in a jacketed reactor, and after 15 min, the reaction mixture was heated at 85 °C for 15 min, to deactivate the protease. The product obtained was centrifuged at 9500g for 15 min, and the supernatant was collected. The chia protein hydrolysates (CPHs) obtained were designated as CPH15A.

2.3. Characterization of the Mineral Content by Inductively Coupled Plasma. A microwave-assisted digestion procedure was carried out to quantify the mineral content of the CPH15A. Reagents employed for digestion were HNO<sub>3</sub> and  $H_2O_2$ , with a temperature of 200 °C. The analysis was done employing a plasma optical emission spectrometer [inductively coupled plasma (ICP), SpectroBlue].<sup>15</sup>

**2.4. Molecular Weights by UHPLC.** Molecular weights (MWs) were estimated by size exclusion chromatography (SEC) on an Acquity Arc equipped with a 2998PDA Detector, a Sample Manager FTN-R, and a Quaternary Solvent Manager-R (Acquity Arc, Waters Corporation, Milford, MA, USA) with a XBridge TM Protein BEH SEC 200 Å 2.5  $\mu$ m 4.6 mm × 150 mm column. The standard proteins (Waters Corporation, Milford, MA, USA) were used to calibrate the column: uracil (0.112 kDa), ribonuclease A (13.7 kDa), albumin chicken egg white (44.2 kDa), and thyroglobulin bovine (669 kDa).<sup>3</sup> A volume of 10  $\mu$ L dissolved in 100 mM

sodium phosphate buffer and 0.02% (w/v) sodium azide adjusted at pH 6.8 at a concentration of 1 mg/mL was injected. Protein elution was recorded by measuring its absorbance at 280 nm and analyzed with Empower 3 Personal GPC/SEC software (Waters Corporation, Milford, MA, USA).

**2.5. Ultrastructural Characterization by Scanning Electron Microscopy Analysis.** Ultrastructural characterization of the samples (defatted flour, concentrates, and CPH15A) was performed by using scanning electron microscopy (SEM). A description of the methodology can be found in Montserrat-de la Paz et al.,<sup>16</sup>

**2.6. In Vitro Availability Using Caco-2 Cell Culture.** Caco-2 cells were cultured in 12-well cell culture inserts in Dulbecco's modified Eagle medium, supplemented with 10% heat-inactivated FBS and 1% penicillin/streptomycin. Cells were incubated at 37 °C under a modified atmosphere of 5%  $CO_2$  and given a fresh medium every 2–3 days. Cell monolayer integrity was monitored by transepithelial electrical resistance using a Millicell ERS-2 voltammeter (Millipore). Inserts were used for 2 weeks after seeding and had a resistance of at least 500 W/cm<sup>2</sup>. Inserts were transferred to 12-well plates and were initiated by replacing the medium with fresh medium containing CPH15A dissolved in distilled water at 1 mg/mL in the apical chamber. After 4 h, the content on the basolateral side was recovered in PBS.

**2.7. Peptide Extraction, Purification, and Sequence Identification by LC-TIMS-MS/MS.** Samples were acidified with 0.5% trifluoroacetic acid. The desalting and concentration step was performed with ZipTip C18 (Millipore), the digested samples were speed-vacuum-dried, and the total protein content was analyzed by a bicinchoninic acid assay. LC-TIMS-MS/MS was carried out using a nanoElute nanoflow ultrahigh-pressure LC system (Bruker Daltonics, Bremen, Germany) coupled to a timsTOF Pro 2 mass spectrometer equipped with a CaptiveSpray nanoelectrospray ion source (Bruker Daltonics). Details of the methodology can be found in Montserrat-de la Paz et al.,<sup>16</sup> although in this case, the reference library is acquired from UniProt\_proteome\_Salvia-ssp Feb22.

**2.8.** In Silico Analysis. The peptides chosen from the pool of peptides identified (criteria: from those with molecular weight <1000 Da); the first 20 with higher statistical significance of the peptide-precursor spectrum match (according to the  $-10 \lg P$  value) from the bioavailable hydrolysate were subjected to in silico analyses: (a) ToxinPred software was employed to predict hydrophobicity, charge, isoelectric point, amphipathicity, steric hindrance, toxicity, and molecular weight of the peptides (https://webs.iiitd.edu.in/raghava/ toxinpred/design.php);<sup>17</sup> (b) PeptideRanker, which predicts probability to be bioactive (http://bioware.ucd.ie/~compass/ biowareweb), giving an score from 0 to 1.0 at a threshold of 0.5;<sup>18</sup> (c) AnOxPePred-1.0 was employed to predict the antioxidant (quantified by free radical scavenging and ion chelating scores) properties of peptides using convolutional neural network (https://services.healthtech.dtu.dk/service. php?AnOxPePred-1.0),<sup>19</sup> (d) mAHTPred was used for predicting ACE inhibitors property of peptides using effective feature representation (http://thegleelab.org/mAHTPred/ index.html). The assigned scores ranged from 0 to 1.0 at a threshold of 0.5;<sup>20</sup> (e) Computational molecular stability: the web server PASTA 2.0 (http://protein.bio.unipd.it/pasta2/) was used to compute the tendency of peptide self-aggregation and the predicted amyloid-like structure (parallel/antiparallel **2.9. In Silico Digestion of Bioactive Peptides.** The tool BIOPEP, which can be found at https://biochemia.uwm.edu. pl/biopep/rec\_prol.php?x=72&y=0, was employed to carry out an in silico gastrointestinal digestion of the peptides identified by entering the peptide sequences and predicting the potential sites cleaved by pepsin, chymotrypsin, and trypsin, aiming to predict the potential new species produced after digestive degradation. Then, these fragments were screened to see if they were ACE inhibitory or antioxidant sequences, according to the database.

2.10. Molecular Docking and Ligand-Interaction Visualization. Molecular docking was carried out to determine the binding affinity energy of the peptides with the ACE (Angiotensin Converting Enzyme) receptor. The Xray crystal structure of the enzyme (PDB: 108A) was obtained from the RCSB PDB database (Protein Data Bank, http:// www.rcsb.org/). Ligands and all the water molecules were removed from the receptor PDB file, while the polar hydrogen atoms were added, and the structure was minimized using UCSF Chimera software. The 3D structures of the two selected peptides were obtained with a USCF Chimera. Following that, the molecular structures of ACE and the peptides were converted to the PDBQT format with AutoDock Tools. The AGFR program was employed to determine the positions and sizes of the specific docking boxes for the selected sequences. Next, AutoDock Crank Pep was employed to perform docking analysis with the peptides. The potential best docking score determined was chosen and visualized via Biovia Discovery Studio Visualizer, as well as the twodimensional (2D) and surface annotation of both ligand interactions with the protein.

**2.11. Statistical Analysis.** All values are presented as means  $\pm$  standard deviations (SD). Data were evaluated using Graph Pad Prism version 9.1.2 (San Diego, CA, USA). The statistical significance of the antioxidant activity between the groups was assessed using a two-way analysis of variance (ANOVA), followed by Tukey's multiple-comparison test. *P* values less than 0.05 were considered to be statistically significant.

#### 3. RESULTS AND DISCUSSION

3.1. Characterization. In previous reports, a characterization of the CPH15A was carried out, including its chemical composition, techno-functional properties (oil absorption capacity and capacity and stability of foaming and emulsifying), and cell-free bioactive properties (antioxidant and ACE inhibitors).<sup>3</sup> The half maximal inhibitory concentration  $(IC_{50})$  value for inhibiting angiotensin converting enzyme (ACE) was 78.84  $\pm$  1.21 µg/mL. The protein content of CPH15A was 75.03%, whereas the remaining fractions comprised fiber (11.2%), moisture (7.32%), and ash (6.45%). The amino acid profile of the hydrolysate was in line with the FAO/WHO/UNU nutritional recommendations for adults for essential amino acids. Among the nonessential ones, the majority are the negatively charged amino acids, glutamic acid and aspartic acid, in an amount of 178.3 and 84.5 mg/g protein, respectively, and the positively charged arginine  $(105.3 \text{ mg/g protein}).^3$ 

CPH15A has been shown to be a promising ingredient to be employed to fortify foods, based on its improved properties. A more detailed characterization will provide a deeper insight into its nutritional properties and the molecules responsible for the bioactivity reported. In this work, the mineral content of CPH15A was evaluated. In Table 1, the results of the

| Table 1. Mineral | Content of | CPH15A | by ICP <sup>a</sup> |
|------------------|------------|--------|---------------------|
|------------------|------------|--------|---------------------|

| element                          | CPH15A (mg/kg)                        |
|----------------------------------|---------------------------------------|
| calcium                          | $195.65 \pm 0.02$                     |
| cobalt                           | ≤0.25                                 |
| chromium                         | ≤0.25                                 |
| iron                             | $46.94 \pm 0.00$                      |
| potassium                        | $142.29 \pm 0.02$                     |
| magnesium                        | $16.06 \pm 0.00$                      |
| manganese                        | $0.25 \pm 0.00$                       |
| sodium                           | $21195.65 \pm 1.98$                   |
| nickel                           | ≤0.25                                 |
| phosphorus                       | $1711.96 \pm 0.06$                    |
| sulfur                           | $12,500 \pm 0.20$                     |
| selenium                         | ≤1.73                                 |
| vanadium                         | ≤0.25                                 |
| zinc                             | $3.71 \pm 0.00$                       |
| Values expressed as mean content | $\pm$ standard deviation ( $n = 3$ ). |

elemental analysis in mg/kg are reported. The element found in the highest amount was sodium, which is due to the alkali necessary to keep the pH constant during the hydrolysis process as well as the intrinsic content of chia. The content of sulfur mostly derives from the amount of cysteine and methionine quantified in the hydrolysate (40.32 mg/g protein).<sup>2</sup> A balanced mineral content is important to treat the deficiency in the diet of these in the population, such as the potassium content, whereas it is also important to take into consideration the tolerable upper intake levels for essential minerals, not to lead to a nutritionally disadvantageous ingredient.

Kulczyński et al.<sup>22</sup> reviewed the chemical composition and nutritional value of chia seeds, indicating phosphorus (860-919 mg/100 g), calcium (456-631 mg/100 g), potassium (407-726 mg/100 g), and magnesium (335-449 mg/100 g) as the most abundant ones. According to the bioprocess, the content of minerals is not comparable to the hydrolysate, as it is obtained from the protein isolate, and consequently, the amount of each fraction is not the same. However, this characterization demonstrates that CPH15A still supplies many minerals and is nutritionally interesting for human consumption.

In addition, SEM analysis (Figure 1) showed how the surface morphology of the original chia sample changed after hydrolysis. It is observed that the protein presented in the chia defatted flour and CPI has been degraded into small fragments after the proteolytic action of Alcalase, cleaving several peptidic bonds and, as a consequence, leading to a reduction in particle size under the same SEM parameters (Mag =  $345 \times$  and AV = 2.0 kV/Mag =  $1.5k \times$  and AV = 2.0 kV). These findings are similar to recently reported changes in the ultrastructural characterization of protein hydrolysates obtained from hemp or turtlegrass, which are additionally correlated with an increased solubility of the samples.<sup>16,23</sup>

**3.2.** Peptidome Profile. 3.2.1. Peptides Identified in CPH15A. The peptidome of CPH15A was fully characterized by LC-TIMS-MS/MS. In the original hydrolysate, a total of 1868 peptides were identified. The average length of all the



**Figure 1.** Surface characteristics of chia defatted flour (CDF), chia protein concentrate (CPC), and the CPC after 15 min of hydrolysis with Alcalase (CPH15A) by scanning electron microscopy (SEM) at two magnifications (Mag.). Upper SEM images (A–C) were taken at Mag =  $345 \times$  and AV = 2.0 kV. Lower SEM images (D–F) were taken at Mag =  $1.5k \times$  and AV = 2.0 kV.



Figure 2. Molecular weight (MW) profiles by UHPLC chromatogram of CPH15A and bioavailable CPH15A.

peptides identified is 12 residues, but sequences up to 26 amino acids were identified. The average length of the 20 selected peptides was 15 residues. Only around 12% of the sample corresponded to <1000 Da peptides (based on the peptidome obtained, not from the SEC analysis). The degree of hydrolysis of the sample was determined to be 36.2%.<sup>3</sup> The profile of peptides released after enzymatic hydrolysis depends mostly on the specificity of the protease and the duration of the reaction. As shown in Figure 2, the protein molecular profile by UHPLC of CPH15A and bioavailable CPH15A showed that the peptide size was both similar, around 3-0.2 kDa and 5.9-6.6 retention time, respectively. This result showed that enzymatic hydrolysis using Alcalase significantly produced bioavailable peptides. In this case, Alcalase shows subtilisin activity, which is an endopeptidase that is highspectrum, nonspecific, and would cleave mainly hydrophobic amino acids.<sup>24</sup>

Due to the technique employed for the identification of peptides, the sequence of high-molecular-weight proteins such as globulins is not reported in the outcome of this analysis, but it encompasses only the peptide up to a certain amino acid length. In the scope of this manuscript, the focus is on peptides below 1000 Da, as they are expected to be bioactive<sup>25,26</sup> because of their ability to enter cells. Chia is not a substrate as widely studied as other common protein sources, such as fish or milk.<sup>27</sup> However, there is only recently published literature reporting the identification of peptides from chia. For instance, five sequence peptides (NNVFYPF, FNIVFPG, SRPWPIDY, QLQRWFR, and GSRFDWTR) were identified by Aguilar-Toalá et al.<sup>5</sup> Similar to NNVFYPF, in the original hydrolysate, the peptides RNNVFYPFD, RNNVFYPFE, and RNNVFYPF were identified. Similarly, other peptides containing those identified by these authors were found in the hydrolysate under assessment and will be further discussed in the following

 Table 2. Physical-Chemical Characterization of the Selected Peptide Sequences Identified in Bioavailable Chia Protein

 Hydrolysate (CPH15A) Based on in silico Analyses<sup>a</sup>

| peptide   | -10 lg P | molec. weight | res. length | hydrophobicity | steric hindrance | amphipathicity | charge | pI    |
|-----------|----------|---------------|-------------|----------------|------------------|----------------|--------|-------|
| IVDHSGQTM | 55.43    | 986.45        | 9           | -0.06          | 0.60             | 0.30           | -0.50  | 5.09  |
| VVDHSGQTM | 55.21    | 972.43        | 9           | -0.08          | 0.60             | 0.30           | -0.50  | 5.09  |
| HGPIKLH   | 52.44    | 800.47        | 7           | -0.08          | 0.42             | 0.94           | 2.00   | 9.11  |
| AGDAHWTY  | 51.82    | 919.38        | 8           | -0.03          | 0.53             | 0.18           | -0.50  | 5.09  |
| TNAPRLTF  | 49.87    | 918.49        | 8           | -0.18          | 0.58             | 0.31           | 1.00   | 10.11 |
| KNLDHPTSA | 48.76    | 981.49        | 9           | -0.29          | 0.52             | 0.57           | 0.50   | 7.09  |
| VDAHPIKAM | 47.92    | 980.51        | 9           | -0.03          | 0.56             | 0.57           | 0.50   | 7.09  |
| FSEDNVKVG | 47.77    | 993.48        | 9           | -0.17          | 0.69             | 0.55           | -1.00  | 4.38  |
| YTNAPRLT  | 47.67    | 934.49        | 8           | -0.25          | 0.58             | 0.31           | 1.00   | 9.10  |
| PNYHPNPR  | 46.79    | 993.48        | 8           | -0.45          | 0.50             | 0.49           | 1.50   | 9.10  |
| AEKGTLFPN | 45.33    | 975.50        | 9           | -0.12          | 0.60             | 0.55           | 0.00   | 6.35  |
| SHKLPILN  | 44.14    | 920.54        | 8           | -0.09          | 0.51             | 0.64           | 1.50   | 9.11  |
| KQGDVIAIR | 43.37    | 998.59        | 9           | -0.21          | 0.68             | 0.82           | 1.00   | 9.10  |
| HQQIGFLK  | 42.94    | 969.54        | 8           | -0.11          | 0.58             | 0.95           | 1.50   | 9.11  |
| VKEPVFSF  | 42.61    | 951.51        | 8           | 0.03           | 0.63             | 0.62           | 0.00   | 6.35  |
| YTNAPRL   | 41.75    | 833.44        | 7           | -0.26          | 0.58             | 0.35           | 1.00   | 9.10  |
| ALPPGAVHW | 41.33    | 946.50        | 9           | 0.17           | 0.46             | 0.16           | 0.50   | 7.10  |
| NDGDAPLTY | 41.26    | 964.41        | 9           | -0.15          | 0.62             | 0.00           | -2.00  | 3.57  |
| HRQPQLN   | 40.06    | 891.47        | 7           | -0.53          | 0.53             | 0.91           | 1.50   | 10.11 |
| DAREPSYR  | 39.62    | 992.47        | 8           | -0.61          | 0.61             | 0.77           | 0.00   | 6.42  |

"Peptides were subjected to calculation via http://pepcalc.com/, where the net charge at neutral pH was calculated. Meanwhile, peptide solubility in pure water was estimated on this web server based on the combined results of the isoelectric point (pI), the number of charged residues, and the peptide length. Peptides were subjected to calculation via https://webs.iiitd.edu.in/raghava/toxinpred/design.php/, where the hydrophobicity, steric hindrance, and amphipathicity were calculated.

Table 3. Bioactivity Prediction (i.e., Free Radical Scavenger, Chelation Score, and ACE Inhibitors Property) and Digestion of the Selected Peptide Sequences Identified in Bioavailable Chia Protein Hydrolysate (CPH15A) Based on In Silico Analyses<sup>a</sup>

| peptide   | -10 lg P | likelihood of being<br>bioactive | free radical scavenger<br>score | chelation<br>score | mAHTPred | BIOPEP SGID   | active fragments           |
|-----------|----------|----------------------------------|---------------------------------|--------------------|----------|---------------|----------------------------|
| IVDHSGQTM | 55.43    | 0.163                            | 0.411                           | 0.267              | 0.13     | IVDH-SGQTM    | no                         |
| VVDHSGQTM | 55.21    | 0.133                            | 0.442                           | 0.257              | 0.10     | VVDH-SGQTM    | no                         |
| HGPIKLH   | 52.44    | 0.450                            | 0.420                           | 0.251              | 0.27     | H-GPIK-L-H    | no                         |
| AGDAHWTY  | 51.82    | 0.605                            | 0.532                           | 0.217              | 0.11     | AGDAH-W-TY    | TY (antioxidant)           |
| TNAPRLTF  | 49.87    | 0.499                            | 0.358                           | 0.229              | 0.23     | TN-APR-L-TF   | TF (ACE inhibitor)         |
| KNLDHPTSA | 48.76    | 0.157                            | 0.403                           | 0.258              | 0.24     | K-N-L-DH-PTSA | no                         |
| VDAHPIKAM | 47.92    | 0.517                            | 0.451                           | 0.280              | 0.51     | VDAH-PIK-AM   | no                         |
| FSEDNVKVG | 47.77    | 0.256                            | 0.327                           | 0.200              | 0.09     | F-SEDN-VK-VG  | VK, VG (ACE<br>inhibitors) |
| YTNAPRLT  | 47.67    | 0.473                            | 0.392                           | 0.212              | 0.18     | Y-TN-APR-L-T  | no                         |
| PNYHPNPR  | 46.79    | 0.751                            | 0.603                           | 0.283              | 0.85     | PN-Y-H-PN-PR  | PR (ACE inhibitor)         |
| AEKGTLFPN | 45.33    | 0.392                            | 0.377                           | 0.211              | 0.15     | AEK-GTL-F-PN  | no                         |
| SHKLPILN  | 44.14    | 0.440                            | 0.356                           | 0.267              | 0.54     | SH-K-L-PIL-N  | no                         |
| KQGDVIAIR | 43.37    | 0.238                            | 0.271                           | 0.180              | 0.11     | K-QGDVIAIR    | no                         |
| HQQIGFLK  | 42.94    | 0.547                            | 0.386                           | 0.234              | 0.10     | H-QQIGF-L-K   | no                         |
| VKEPVFSF  | 42.61    | 0.442                            | 0.354                           | 0.204              | 0.75     | VK-EPVF-SF    | VK, SF (ACE<br>inhibitors) |
| YTNAPRL   | 41.75    | 0.297                            | 0.421                           | 0.223              | 0.76     | Y-TN-APR-L    | no                         |
| ALPPGAVHW | 41.33    | 0.656                            | 0.471                           | 0.257              | 0.83     | AL-PPGAVH-W   | no                         |
| NDGDAPLTY | 41.26    | 0.382                            | 0.384                           | 0.241              | 0.12     |               |                            |
| HRQPQLN   | 40.06    | 0.301                            | 0.406                           | 0.266              | 0.36     | N-DGDAPL-TY   | TY (antioxidant)           |
| DAREPSYR  | 39.62    | 0.310                            | 0.410                           | 0.249              | 0.17     | DAR-EPSY-R    | no                         |

"The likelihood of the peptides being bioactive was evaluated by PeptideRanker (http://bioware.ucd.ie/~compass/biowareweb), a server to predict bioactive peptides based on a novel N to-1 neural network, by giving scores ranging from 0 to 1. A higher score indicated a greater likelihood of the peptide being bioactive. AnOxPePred tool (http://services.bioinformatics.dtu.dk/service.php?AnOxPePred-1.0) uses deep learning to predict the antioxidant properties (quantified by free radical scavenging and ion chelating scores) of peptides by giving scores ranging from 0 to 1. BIOPEP SGID refers to BIOPEP-simulated gastrointestinal digestion. Active fragments are those among the products that originated and are considered ACE inhibitory fragments, according to the information contained in the database.

sections. Further research is required to explore how different proteases would release a different profile of peptides from the

same substrate, as this will determine their applicability as functional ingredient.

3.2.2. Bioavailable Peptides Identified after the Cell Culture Assay. In the bioavailable hydrolysate, a total of 1182 peptides were identified, 63% of the original hydrolysate. The average length of all of the peptides identified is 10 residues. It must be taken into consideration two factors when comparing the hydrolysate and the bioavailable hydrolysate: (i) Caco-2 cells: these can differentiate into monolayers with a phenotype with many functions of the small intestinal villus epithelium. Many brush-border enzymes and transport proteins mediate the active transport or efflux of molecules in these cells;<sup>28</sup> as a consequence, the peptides going through these cells would be likely subjected to some kind of modification, mainly cleavage. (ii) The limitation of the technique employed to identify the peptidome: the parameters would include the peptides identified only if found in a minimum amount. However, this limitation lacks relevance as, if not detected, their contribution to bioactivity is likely to be negligible.

Focusing on <1000 Da peptides, 81 sequences were identified both in the hydrolysate before and after being subjected to absorption simulation in the transwell system. These sequences are able to cross the intestinal barrier without suffering any kind of modification, as explained previously. For instance, of the three peptides similar to NNVFYPF,<sup>5</sup> two (RNNVFYPFE and RNNVFYPF) were identified as bioavailable in our research, whereas RNNVFYPFD demonstrated that it did not cross the barrier or was not identified in a sufficient amount.

It has been previously described that the presence of the amino acid arginine at the terminal of the sequences might contribute to an increased resistance to gastrointestinal digestion since the digestive proteases are specific toward these amino acids.<sup>29</sup> This statement is in line with the results obtained since 12 out of the 81 peptides (15% of the total) identified possess R in the N-terminal and 13 of them at the Cterminal (16%). Other bioactive peptides from plant sources, such as GPETAFLR, isolated from a protein hydrolysate from Lupinus angustifolius L., have arginine in their sequence, which may be one of the reasons for their anti-inflammatory potential.<sup>30</sup> The peptide REGADFVR possesses two terminals with arginine. On top of that, several studies have reported the maintainance, loss, or gain of peptides after simulation of digestion using Alcalase, and this would depend on the sequences of the hydrolysate.<sup>29,31</sup>

Considering that the <1000 Da peptides identified in the bioavailable fraction are more likely to be bioactive, the 20 with higher statistical significance of the peptide-precursor spectrum match where subjected to in silico analyses to evaluate their bioactive potential. Out of these 20 peptides, 11 were also identified in the original hydrolysate, whereas the other 9 were not. The identification of peptides before and after being subjected to absorption-simulator models is relevant to evaluating if the peptides exerting bioactivity are maintained or modified, and it gives an answer to whether encapsulation might be needed to stabilize the peptides as nutraceuticals before being incorporated into a food matrix.<sup>32</sup>

**3.3.** In-Silico Analyses of Bioavailable Peptides. In Table 2, the physical-chemical properties (i.e., net charge, isoelectric point (pI), hydrophobicity, steric hindrance, and amphipathicity) and in Table 3 the likelihood to be bioactive and the outcome from bioactivity prediction tools (i.e., free radical scavenger, chelation score, and ACE inhibitor property) and the in silico digestion products of each peptide are shown.

According to the outcome of the ToxinPred software analysis, none of the peptides are predicted to be toxic. Regarding the physic-chemical parameter, and as expected from an Alcalaseaided hydrolysis, the hydrophobicity shows in most of the peptides promising values and, as shown in the literature, can be positively correlated with bioactivity.

Focusing on the value obtained from the antioxidant peptide predictor, the sequences PNYHPNPR, AGDAHWTY, ALPP-GAVHW, and VDAHPIKAM have the highest free radical scavenger score, and in addition, PNYHPNPR and VDAHPI-KAM are those with the highest chelation score. This result offers an idea of the peptides of CPH1SA that could highly contribute to the antioxidant activity of the hydrolysate,<sup>3</sup> as well as the immunomodulatory<sup>2</sup> activity since the hydrolysate proved to reduce reactive oxygen species and nitrite output as well as proinflammatory cytokine secretion and enhance the expression and release of anti-inflammatory cytokines.

In addition, concerning the likelihood of being bioactive, according to Mooney et al.,<sup>33</sup> a score >0.5 strongly suggests that the peptide is bioactive based on its molecular characteristics. It is interesting to see that the peptides that meet this characteristic are the same ones that reported high levels of antioxidant capacity according to the AnOxPred tool, in addition to the HQQIGFLK sequence, which, despite presenting a value higher than the established bioactivity threshold, does not report very high values of antioxidant activity in the tool used. This increases the evidence that these peptides are responsible for the bioactivity of the hydrolysate and could reach the target organs in vivo, as they have proved to be bioavailable in the cell model employed in this research.

Based on the physico-chemical characteristics of the individual peptides, it has been suggested that low steric hindrance values and high amphipathicity could contribute to increasing the bioactivity because they help stabilize the interaction of the peptide with the target compound.<sup>34,35</sup> The peptides with the highest amphipathicity were HGPIKLH, HQQIGFLK, and HRQPQLN, which also showed adequate values in the other prediction tools employed and consequently could be also considered bioactive peptides from chia seeds.

León-Madrazo and Segura Campos<sup>4</sup> carried out an in silico prediction of antimicrobial, antibiofilm, and antioxidant peptides from chia (S. hispanica L.) and indicated, in terms of antioxidant capacity, that the fragment LK is biologically relevant. This fragment was found in the peptide HQQIGFLK in the hydrolysate obtained, which was reported as bioactive according to the prediction tool aforementioned. In a similar way, Grancieri et al.,<sup>36</sup> carried out molecular docking with many chia-derived peptides (e.g., TGPSPTAGP, PAPGGGTH, SPKDLALPPGALPPV, and HYGGPPGG) in order to elucidate their metal chelation or hydrogen/electron donor ability, as well as their potential interaction with inflammation and atherosclerosis markers. Although these peptides were not identified in our hydrolysate, some matching sequences were found, the most extensive being ALPPGA, which appears in SPKDLALPPGALPPV, from the peptides of Grancieri et al.<sup>36</sup> and in ALPPGAVHW of bioavailable CPH15A, demonstrating that the peptides that make up chia proteins are a promising source of bioactive peptides. A peptide can exert antioxidant activity according to the residues in its sequence and how the functional groups of these amino acids can interact with the reactive oxygen species and counteract their effect. It has been proposed that the presence

| IVDHSGQTM         55.43         1-4 (NI)         100         100           VVDHSGQTM         55.21         1-4 (NI)         100         100           HGPIRLH         52.44         4-7 (NI)         100         100           AGDAHWTY         51.82         4-8 (NI)         100         100           TNAPRLTF         49.87         5-8 (NI)         100         100           KNLDHPTSA         48.76         2-5 (NI)         100         100           VDAHPIKAM         47.92         1-4 (NI)         100         100           VTNAPRLT         47.67         1-4 (NI)         100         100           YTNAPRLT         47.67         1-4 (NI)         100         100           SHKLPILN         44.14         4-7 (NI)         100         100           SHKLPILN         44.14         4-7 (NI)         100         100           VKepVFSF         42.61         5-8 (NI)         100         100 <th>peptide</th> <th>-10 lg P</th> <th>self-aggregation-prone region &amp; amyloids</th> <th>disorder probability (%)</th> <th colspan="2">probability in secondary structu</th> <th>ructure (%)</th> | peptide   | -10 lg P | self-aggregation-prone region & amyloids | disorder probability (%) | probability in secondary structu |                 | ructure (%) |
|---|-----------|----------|--|--------------------------|----------------------------------|-----------------|-------------|
| IVDHSGQTM         55.43         1-4 (NI)         100         100           VVDHSGQTM         55.21         1-4 (NI)         100         100           HGPIKLH         52.44         4-7 (NI)         100         100           AGDAHWTY         51.82         4-8 (NI)         100         100           TNAPRLTF         49.87         5-8 (NI)         100         100           KNLDHPTSA         48.76         2-5 (NI)         100         100           VDAHPIKAM         47.92         1-4 (NI)         100         100           VDAHPIKAM         47.92         1-4 (NI)         100         100           VTNAPRLT         47.67         1-4 (NI)         100         100           VTNAPRLT         47.67         1-4 (NI)         100         100           PNYHPNPR         46.79         2-5 (NI)         100         100           AEKGTLFPN         45.33         4-7 (NI)         100         100           SHKLPILN         41.14         4-7 (NI)         100         100           KQGDVIAIR         43.37         5-8 (PA)         100         100           VEPVFSF         42.61         5-8 (NI)         100         100  |           |          |  |                          | $\alpha$ -helix                  | $\beta$ -strand | coil        |
| VVDHSGQTM         55.21         1-4 (NI)         100         100           HGPIKLH         52.44         4-7 (NI)         100         100           AGDAHWTY         51.82         4-8 (NI)         100         100           TNAPRLTF         49.87         5-8 (NI)         100         100           KNLDHPTSA         48.76         2-5 (NI)         100         100           VDAHSQUM         47.92         1-4 (NI)         100         100           VDAHPIKAM         47.92         1-4 (NI)         100         100           VDAHPIKAM         48.76         2-5 (NI)         100         100           VDAHPIKAM         48.76         2-5 (NI)         100         100           VTNAPRLT         47.67         1-4 (NI)         100         100           PNYHPNR         46.79         2-5 (NI)         100         100           AEKGTLFPN         45.33         4-7 (NI)         100         100           KQGDVIAIR         43.37         5-8 (PA)         100         44.44         55.56           HQQIGFLK         42.61         5-8 (NI)         100         100         100           VEPVFSF         42.61         5-8 (NI)   | IVDHSGQTM | 55.43    | 1–4 (NI)                                 | 100                      |                                  |                 | 100         |
| HGPIKLH52.444–7 (NI)100100AGDAHWTY51.824–8 (NI)100100TNAPRLTF49.875–8 (NI)100100KNLDHPTSA48.762–5 (NI)100100VDAHPIKAM47.921–4 (NI)100100FSEDNVKVG47.775–8 (NI)100100FSEDNVKVG47.775–8 (NI)100100FSEDNVKVG47.775–8 (NI)100100PNYHPNR46.792–5 (NI)100100PNYHPNR46.792–5 (NI)100100SHKLPILN44.144–7 (NI)100100KQGDVIAIR43.375–8 (PA)10044.44S5.56HQQIGFLK42.944–7 (NI)100100VKEPVFSF42.615–8 (NI)100100100VTNAPRL41.751–4 (NI)100100100NDGDAPLTY41.266–9 (NI)100100100HRQPQLN40.061–4 (NI)100100100HRQPQLN40.061–4 (NI)100100100NDGDAPLTY41.266–9 (NI)100100100HRQPQLN40.061–4 (NI)100100100NAREPSYR39.624–8 (NI)100100100   | VVDHSGQTM | 55.21    | 1–4 (NI)                                 | 100                      |                                  |                 | 100         |
| AGDAHWTY       \$1.82       4-8 (NI)       100       100         TNAPRLTF       49.87       \$-8 (NI)       100       100         KNLDHPTSA       48.76       2-5 (NI)       100       100         VDAHPIKAM       47.92       1-4 (NI)       100       100         FSEDNVKVG       47.77       \$-8 (NI)       100       100         FSEDNVKVG       47.77       \$-8 (NI)       100       100         FYNAPRLT       47.67       1-4 (NI)       100       100         PNYHPNPR       46.79       2-5 (NI)       100       100         AEKGTLFPN       45.33       4-7 (NI)       100       100         SHLPILN       44.14       4-7 (NI)       100       100         KQGDVIAIR       43.37       \$-8 (PA)       100       44.44       55.56         HQQIGFLK       42.94       4-7 (NI)       100       100       100         VKEPVFSF       42.61       \$-8 (NI)       100       100       100         VKEPVFSF       42.61       \$-8 (NI)       100       100       100         MQGDAPLTY       41.75       1-4 (NI)       100       100       100         NDGDAPLTY  | HGPIKLH   | 52.44    | 4–7 (NI)                                 | 100                      |                                  |                 | 100         |
| TNAPRLTF49.875-8 (NI)100100KNLDHPTSA48.762-5 (NI)100100VDAHPIKAM47.921-4 (NI)100100FSEDNVKVG47.775-8 (NI)100100YTNAPRLT47.671-4 (NI)100100PNYHPNPR46.792-5 (NI)100100AEKGTLFPN45.334-7 (NI)100100SHKLPILN44.144-7 (NI)100100KQGDVIAIR43.375-8 (PA)10044.44VEPVFSF42.615-8 (NI)100100VKEPVFSF42.615-8 (NI)100100VKEPVFSF42.615-9 (NI)100100MDGDAPLTY41.266-9 (NI)100100NDGDAPLTY40.061-4 (NI)100100NDGDAPLTY39.624-8 (NI)100100  | AGDAHWTY  | 51.82    | 4–8 (NI)                                 | 100                      |                                  |                 | 100         |
| KNLDHPTSA48.762–5 (NI)100100VDAHPIKAM47.921–4 (NI)100100FSEDNVKVG47.775–8 (NI)100100YTNAPRLT47.671–4 (NI)100100PNYHPNPR46.792–5 (NI)100100AEKGTLFPN45.334–7 (NI)100100SHKLPILN44.144–7 (NI)100100KQGDVIAIR43.375–8 (PA)10044.44VEPVFSF42.615–8 (NI)100100VKEPVFSF42.615–8 (NI)100100VKEPVFSF42.615–8 (NI)100100NDGDAPLTY41.266–9 (NI)100100HQQQLN40.061–4 (NI)100100NDGDAPLTY43.924–8 (NI)100100NDGDAPLTY43.936–9 (NI)100100NDGDAPLTY41.266–9 (NI)100100NDGDAPLTY43.961–4 (NI)100100NDGDAPLTY43.961–4 (NI)100100NDGDAPLTY43.961–4 (NI)100100NDGDAPLTY43.961–4 (NI)100100NDGDAPLTY43.961–4 (NI)100100NDGDAPLTY43.961–4 (NI)100100NDGDAPLTY43.961–4 (NI)100100NDGDAPLTY43.961–4 (NI)100100NDGDAPLTY43.961–4 (NI)100100<   | TNAPRLTF  | 49.87    | 5–8 (NI)                                 | 100                      |                                  |                 | 100         |
| VDAHPIKAM         47.92         1-4 (NI)         100         100           FSEDNVKVG         47.77         5-8 (NI)         100         100           YTNAPRLT         47.67         1-4 (NI)         100         100           PNYHPNPR         46.79         2-5 (NI)         100         100           AEKGTLFPN         45.33         4-7 (NI)         100         100           SHKLPILN         44.14         4-7 (NI)         100         100           KQGDVIAIR         43.37         5-8 (PA)         100         44.44         55.56           HQQIGFLK         42.94         4-7 (NI)         100         100         100           VKEPVFSF         42.61         5-8 (NI)         100         100         100           YTNAPRL         41.75         1-4 (NI)         100         100         100           VKEPVFSF         42.61         5-9 (NI)         100         100         100           MDGDAPLTY         41.33         6-9 (NI)         100         100         100           MDGDAPLTY         41.26         6-9 (NI)         100         100         100           HRQPQLN         40.06         1-4 (NI)         100         100<  | KNLDHPTSA | 48.76    | 2–5 (NI)                                 | 100                      |                                  |                 | 100         |
| FSEDNVKVG47.775-8 (NI)100100YTNAPRLT47.671-4 (NI)100100PNYHPNPR46.792-5 (NI)100100AEKGTLFPN45.334-7 (NI)100100SHKLPILN44.144-7 (NI)100100KQGDVIAIR43.375-8 (PA)10044.4455.56HQQIGFLK42.944-7 (NI)100100100VKEPVFSF42.615-8 (NI)100100100YTNAPRL41.751-4 (NI)100100100MCGDAPLTY41.266-9 (NI)100100100HQPQLN40.061-4 (NI)100100100DAREPSYR39.624-8 (NI)100100100  | VDAHPIKAM | 47.92    | 1–4 (NI)                                 | 100                      |                                  |                 | 100         |
| YTNAPRLT47.671-4 (NI)100100PNYHPNPR46.792-5 (NI)100100AEKGTLFPN45.334-7 (NI)100100SHKLPILN44.144-7 (NI)100100KQGDVIAIR43.375-8 (PA)10044.4455.56HQQIGFLK42.944-7 (NI)100100100VKEPVFSF42.615-8 (NI)100100100YTNAPRL41.751-4 (NI)100100100MCGDAPLTY41.266-9 (NI)100100100HRQPQLN40.061-4 (NI)100100100DAREPSYR39.624-8 (NI)100100100   | FSEDNVKVG | 47.77    | 5–8 (NI)                                 | 100                      |                                  |                 | 100         |
| PNYHPNPR46.792–5 (NI)100100AEKGTLFPN45.334–7 (NI)100100SHKLPILN44.144–7 (NI)100100KQGDVIAIR43.375–8 (PA)10044.4455.56HQQIGFLK42.944–7 (NI)100100100VKEPVFSF42.615–8 (NI)100100100YTNAPRL41.751–4 (NI)100100100ALPPGAVHW41.336–9 (NI)100100100HQQULN40.061–4 (NI)100100100DAREPSYR39.624–8 (NI)100100100   | YTNAPRLT  | 47.67    | 1–4 (NI)                                 | 100                      |                                  |                 | 100         |
| AEKGTLFPN45.334–7 (NI)100100SHKLPILN44.144–7 (NI)100100KQGDVIAIR43.375–8 (PA)10044.4455.56HQQIGFLK42.944–7 (NI)100100100VKEPVFSF42.615–8 (NI)100100100YTNAPRL41.751–4 (NI)100100100ALPPGAVHW41.336–9 (NI)100100100NDGDAPLTY41.266–9 (NI)100100100HRQPQLN40.061–4 (NI)100100100DAREPSYR39.624–8 (NI)100100100  | PNYHPNPR  | 46.79    | 2–5 (NI)                                 | 100                      |                                  |                 | 100         |
| SHKLPILN         44.14         4–7 (NI)         100         100           KQGDVIAIR         43.37         5–8 (PA)         100         44.44         55.56           HQQIGFLK         42.94         4–7 (NI)         100         100           VKEPVFSF         42.61         5–8 (NI)         100         100           YTNAPRL         41.75         1–4 (NI)         100         100           ALPPGAVHW         41.33         6–9 (NI)         100         100           NDGDAPLTY         41.26         6–9 (NI)         100         100           HRQPQLN         40.06         1–4 (NI)         100         100           DAREPSYR         39.62         4–8 (NI)         100         100  | AEKGTLFPN | 45.33    | 4–7 (NI)                                 | 100                      |                                  |                 | 100         |
| KQGDVIAIR43.375–8 (PA)10044.4455.56HQQIGFLK42.944–7 (NI)100100VKEPVFSF42.615–8 (NI)100100YTNAPRL41.751–4 (NI)100100ALPPGAVHW41.336–9 (NI)100100NDGDAPLTY41.266–9 (NI)100100HRQPQLN40.061–4 (NI)100100DAREPSYR39.624–8 (NI)100100  | SHKLPILN  | 44.14    | 4–7 (NI)                                 | 100                      |                                  |                 | 100         |
| HQQIGFLK         42.94         4-7 (NI)         100         100           VKEPVFSF         42.61         5-8 (NI)         100         100           YTNAPRL         41.75         1-4 (NI)         100         100           ALPPGAVHW         41.33         6-9 (NI)         100         100           NDGDAPLTY         41.26         6-9 (NI)         100         100           HRQPQLN         40.06         1-4 (NI)         100         100           DAREPSYR         39.62         4-8 (NI)         100         100   | KQGDVIAIR | 43.37    | 5–8 (PA)                                 | 100                      |                                  | 44.44           | 55.56       |
| VKEPVFSF         42.61         5-8 (NI)         100         100           YTNAPRL         41.75         1-4 (NI)         100         100           ALPPGAVHW         41.33         6-9 (NI)         100         100           NDGDAPLTY         41.26         6-9 (NI)         100         100           HRQPQLN         40.06         1-4 (NI)         100         100           DAREPSYR         39.62         4-8 (NI)         100         100   | HQQIGFLK  | 42.94    | 4–7 (NI)                                 | 100                      |                                  |                 | 100         |
| YTNAPRL41.751-4 (NI)100100ALPPGAVHW41.336-9 (NI)100100NDGDAPLTY41.266-9 (NI)100100HRQPQLN40.061-4 (NI)100100DAREPSYR39.624-8 (NI)100100   | VKEPVFSF  | 42.61    | 5–8 (NI)                                 | 100                      |                                  |                 | 100         |
| ALPPGAVHW41.336-9 (NI)100100NDGDAPLTY41.266-9 (NI)100100HRQPQLN40.061-4 (NI)100100DAREPSYR39.624-8 (NI)100100   | YTNAPRL   | 41.75    | 1–4 (NI)                                 | 100                      |                                  |                 | 100         |
| NDGDAPLTY         41.26         6-9 (NI)         100         100           HRQPQLN         40.06         1-4 (NI)         100         100           DAREPSYR         39.62         4-8 (NI)         100         100   | ALPPGAVHW | 41.33    | 6–9 (NI)                                 | 100                      |                                  |                 | 100         |
| HRQPQLN40.061-4 (NI)100100DAREPSYR39.624-8 (NI)100100   | NDGDAPLTY | 41.26    | 6–9 (NI)                                 | 100                      |                                  |                 | 100         |
| DAREPSYR 39.62 4–8 (NI) 100 100   | HRQPQLN   | 40.06    | 1–4 (NI)                                 | 100                      |                                  |                 | 100         |
|   | DAREPSYR  | 39.62    | 4–8 (NI)                                 | 100                      |                                  |                 | 100         |

 Table 4. Secondary Structure Prediction of the Selected Peptide Sequences Identified in Bioavailable Chia Protein Hydrolysate (CPH15A) Based on In Silico Analyses<sup>a</sup>

<sup>*a*</sup>The web server PASTA 2.0 (http://protein.bio.unipd.it/pasta2/) was implicated in computing the tendency of peptide self-aggregation specific to the possible region at sequence (with the recorded number starting from the N-terminus). For peptide discrimination, the optimal thresholds were switched to top = 1 and energy <-5 PEU (1 PEU (Pasta Energy Unit) = 1.192 kcal/mol). NI: no amyloid predicted; PA: parallel aggregation computed. The probability of intrinsic disorder and the portion of estimated secondary structure that complements the aggregation data were also reported.

of valine (V) at the C-terminal or having tyrosine (Y) in any of the terminals<sup>37</sup> is related to higher antioxidant properties. These features are reported in AGDAHWTY, YTNAPRL, YTNAPRLT, and NDGDAPLTY; indeed, the first one is proposed as highly antioxidant according to the tools, and the rest show an antioxidant score of around 0.4. In the same line, methionine (M) and histidine (H) are considered key contributors in the oxidative stress response because of their reactive oxygen species scavenger properties. These amino acids are also found in some of the peptides identified, including PNYHPNPR, ALPPGAVHW, and VDAHPIKAM, and some others are not predicted to be as highly antioxidant as these two, but that could be adding activity, even if to a lesser extent.

It is really interesting to see the correlation of these results with the outcomes from the prediction of ACE inhibitor peptides. A threshold of 0.5 is described by the authors of the prediction tool, and consequently, the following sequences could be considered ACE inhibitors: VDAHPIKAM, PNYHPNPR, SHKLPILN, VKEPVFSF, YTNAPRL, and ALPPGAVHW, 30% of the 20 selected peptides. The two reported as the most active ACE inhibitors would be PNYHPNPR and ALPPGAVHW, which were also reported as highly antioxidant. These two peptides were found in the hydrolysate before and after being subjected to the bioavailability assay, indicating their resistance to absorption conditions and suggesting their potential to achieve the bloodstream and exert their bioactivity in the target organs. The multifunctionality of peptides obtained from Alcalase has been already reported for chia<sup>5</sup> as well as for other substrates such as insects,<sup>38</sup> and it implies an increase of the value of the manufactured protein hydrolysates. In fact, it has been

reported that ACE inhibitor peptides are usually related to the presence of certain amino acids, including proline (P), phenylalanine (F), tyrosine (Y), or tryptophan (W) at the Cterminal, and valine (V), leucine (L), or isoleucine (I) at the N-terminal.<sup>39</sup> The bioactive potential of chia peptides, as described by Aguilar-Toalá et al.,<sup>5</sup> revealed that the following sequences had the lowest energy score for ACE, suggesting their ACE inhibitory activity: NNVFYPF, FNIVFPG, SRPWPIDY, QLQRWFR, GSRFDWTR, DFKF, DLRF, FKAF, FRSF, and QFRF. Some similarities can be found among this pool of peptides and those identified in the hereby described hydrolysate. For instance, the SF terminal from the peptide FRSF is also found in the one described as highly antioxidant VKEPVFSF, as is the motif VF from FNIVFPG, increasing the evidence that this sequence is highly participating in the antioxidant activity described for the hydrolysate,<sup>3</sup> or, in the same line, the motif PG can be found in the sequence ALPPGAVHW, with a value in the tool of 0.83.

Concerning the isoelectric point of peptides, it has been described that low values are associated with increased antioxidant activity, whereas no evident correlation was observed between this parameter and the ACE inhibitory properties of peptides.<sup>40</sup> Among the four peptides predicted to be highly antioxidant, the sequence AGDAHWTY is reported to have the lowest isoelectric point, whereas ALPPGAVHW is the one with the lowest steric hindrance. Although verification of bioactivity should be carried out employing synthetic peptides, these analyses show the potential of in silico tools in the economic and fast characterization of bioactive peptides.<sup>41</sup> The isoelectric point and amphiphacity of peptides are also important, for instance, when considering their antioxidant



pubs.acs.org/JAFC



Figure 3. Visualization of the peptides-receptor binding (left) and 2D interaction diagram análisis (right) using Biovia Discovery Studio Visualizer. (A) ACE-PNYHPNPR binding site and their interactions with ACE and (B) ACE-ALPPGAHVW binding site and their interactions with ACE.

potential if used in an emulsion, as they can be at the interface between oil and water, stabilizing it.  $^{42}$ 

Taking into account all the parameters discussed, the peptides AGDAHWTY and VDAHPIKAM show promising results in terms of potential antioxidant activity. These peptides were not identified in the original hydrolysate though. This implies that these peptides are released from the hydrolysate due to the activity of the cells, and their concentration has highly increased so that it is quantifiable in the bioavailable fraction. On top of these two, PNYHPNPR and ALPPGAVHW are also proposed as peptides in CPH15A exerting high antioxidant and ACE inhibitor properties, and in this case, they are present in the original hydrolysate, as previously discussed.

On the other hand, the identified peptides were also in silico digested using the BIOPEP tool, as shown in the two last columns of Table 3. Only a few fragments theoretically released after the action of the proteases have been reported as antioxidant or ACE inhibitory sequences, considering the database employed, indicating that these would potentially exert activity after being orally ingested.

Beyond these factors regarding the primary structure of peptides, understanding the advanced conformation of peptides (i.e., secondary structure) also provides an insight into defining bioactive peptides and their role in antioxidant functionality.<sup>21</sup> Herein, as computed by the PASTA 2.0 server (Table 4), 19 of 20 peptide sequences (95% in quantity) derived from CPH15A had the entire probability of rendering a random coil without any contribution to either the  $\alpha$ -helix or the  $\beta$ -strand, and only 1 (KQGDVIAIR) of 20 sequences (5% in quantity) enabled the formation of the  $\beta$ -strand in simulation. Overall, through our computation, the amyloids and self-aggregation were not substantially favored by these peptide monomers of interest, regardless of their hydrophobicity.

Lastly, the two peptides proposed as the most active were analyzed by molecular docking with the ACE enzyme. The affinity of the PNYHPNPR peptide with the ACE was –17.8 kcal/mol, whereas it was –19.5 kcal/mol for the sequence ALPPGAVHW, which is lower than values commonly found in recent literature for peptides interacting with this enzyme,<sup>43,44</sup> indicating the likelihood of these peptides to interact with ACE and exert ACE inhibitory activity. In Figure 3, the 3D representation of the binding site and interactions of these two peptides with the ACE is shown, together with the graphical representation of the interaction occurring, where it can be observed that diverse types of interactions are occurring, leading to a stable complex, supporting the hypothesis that chia-derived peptides are responsible for the inhibition of ACE.

To the authors' knowledge, the hereby identified peptides proposed as antioxidant and ACE inhibitor peptides stemming from a CPH obtained with Alcalase have not been identified previously. In the research field of bioactive peptides, there is still a long way to go. Several limitations (e.g., the in vivo effect of a protein hydrolysate accounts for the whole mixture of peptides and, consequently, the possible synergy effects among peptides) have to be addressed, and improvements in the techniques (peptidomics, in silico prediction tools, etc.) are needed in order to clearly characterize a protein hydrolysate and declare it a functional food. Additionally, investigations in animal models to elucidate the underlying mechanisms by which these peptides would exert in vivo activity and studies in humans to suggest health benefits to the peptides and their efficacy in real food matrices under specific processing and storage circumstances should be carried out. Further research with sustainable sources, such as plant proteins, is necessary in order to modify the current food system and achieve a sustainable and healthy population.

The production of bioactive peptides via enzymatic hydrolysis is a sustainable way to increase the healthpromoting properties of vegetable proteins. A protein isolate obtained from chia seeds was subjected to hydrolysis with a commercially available food-grade endopeptidase in order to produce a hydrolysate with improved techno-functional and biological properties. The hydrolysate was fully characterized, including compositional data and microscopy, and the peptides were identified by LC-TIMS-MS/MS. The hydrolysate was evaluated in a transwell model employing Caco-2 cells to assess the bioavailability of the peptides and how the peptides are modified after their action. The peptides from the bioavailable fraction were also identified, showing relevant differences compared to the original hydrolysate. Twenty peptides having a molecular weight <1000 Da from this bioavailable fraction were subjected to several in silico analyses to determine their contribution to the reported bioactivity (antioxidant and ACE inhibitors) of the hydrolysate. Numerous peptides with adequate molecular features and promising scores in the prediction tools were identified and are proposed to be

antioxidant and ACE inhibitor peptides from *S. hispanica* L seeds. Chia bioactive peptides have demonstrated that they can interact with the body in a multitude of ways to regulate physiological processes in different metabolic pathways throughout the organism, such as by blocking the activity of specific enzymes.

#### ASSOCIATED CONTENT

#### Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jafc.3c05331.

Molecular docking results for the peptides include the affinity of each peptide with the target ACE receptor, the cluster size, and the interaction (position, type, and distance) (Table 1) (PDF)

#### AUTHOR INFORMATION

#### **Corresponding Author**

Sergio Montserrat-de la Paz – Department of Medical Biochemistry, Molecular Biology, and Immunology, School of Medicine, University of Seville, 41009 Seville, Spain; Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, 41013 Seville, Spain; orcid.org/0000-0001-5400-3192; Email: delapaz@us.es

## Authors

- Alvaro Villanueva Department of Food and Health, Instituto de la Grasa (IG-CSIC), 41013 Seville, Spain
- Fernando Rivero-Pino Department of Medical Biochemistry, Molecular Biology, and Immunology, School of Medicine, University of Seville, 41009 Seville, Spain; Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, 41013 Seville, Spain; © orcid.org/0000-0003-1326-7452
- Maria E. Martin Department of Cell Biology, Faculty of Biology, University of Seville, 41012 Seville, Spain
- Teresa Gonzalez-de la Rosa Department of Medical Biochemistry, Molecular Biology, and Immunology, School of Medicine, University of Seville, 41009 Seville, Spain; Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, 41013 Seville, Spain; o orcid.org/0009-0002-2902-0518
- Maria C. Millan-Linares Department of Food and Health, Instituto de la Grasa (IG-CSIC), 41013 Seville, Spain; Department of Medical Biochemistry, Molecular Biology, and Immunology, School of Medicine, University of Seville, 41009 Seville, Spain

Complete contact information is available at: https://pubs.acs.org/10.1021/acs.jafc.3c05331

# **Author Contributions**

Conceptualization: S.M.-d.l.P and M.C.M.-L.; methodology: A.V.; formal analysis: T.R.-d.l.R., F.R.-P., and S.M.-d.l.P.; investigation: A.V.; resources: S.M.-d.l.P and M.C.M.-L.; writing—original draft preparation: F.R.-P.; writing—review and editing: S.M.-d.l.P; supervision: S.M.-d.l.P and M.C.M.-L.; funding acquisition: S.M.-d.l.P. and M.C.M-L. All authors have read and agreed to the published version of the manuscript. All authors have read and agreed to the published version of the manuscript.

#### Funding

This research was funded by grant P20\_00661 from the Andalusian Plan for Research, Development and Innovation (PAIDI) 2020 and by grant US-1381492 from the European Regional Development Fund (ERDF).

#### Notes

The authors declare no competing financial interest.

# ACKNOWLEDGMENTS

M.C.M.-L. acknowledges the financial grant US-1381492 supported by the Andalusian Plan for Research, Development, and Innovation 2020 from the European Regional Development Fund (ERDF). F.R.-P. has the benefit of a Juan de la Cierva postdoctoral fellowship (FJC2022-050043-I) from the Spanish Ministry of Science and Innovation. T.G.-d.l.R. acknowledges his contract supported by the "Programa Investigo" funded by the European Union—Next Generation EU. The authors thank Carlos Fuentes from the Proteomics Unit of the Central Research Support Service of Cordoba University (UCO) for the technical assistance during the fulfillment of this work. This research acknowledges the support provided by grant CYTED-2019/119RT0567 from the Spanish Ministry of Science, Innovation, and Universities.

#### REFERENCES

(1) Motyka, S.; Koc, K.; Ekiert, H.; Blicharska, E.; Czarnek, K.; Szopa, A. The Current State of Knowledge on Salvia Hispanica and Salviae Hispanicae Semen (Chia Seeds). *Molecules* **2022**, *27*, 1207.

(2) Villanueva-Lazo, A.; Montserrat-de-la-Paz, S.; Grao-Cruces, E.; Pedroche, J.; Toscano, R.; Millan, F.; Millan-Linares, M. C. Antioxidant and Immunomodulatory Properties of Chia Protein Hydrolysates in Primary Human Monocyte-Macrophage Plasticity. *Foods* **2022**, *11*, 623.

(3) Villanueva-Lazo, A.; Paz, S. M. d. l.; Rodriguez-Martin, N. M.; Millan, F.; Carrera, C.; Pedroche, J. J.; Millan-Linares, M. D. C. Antihypertensive and Antioxidant Activity of Chia Protein Techno-Functional Extensive Hydrolysates. *Foods* **2021**, *10*, 2297.

(4) León Madrazo, A.; Segura Campos, M. R. *In silico* Prediction of Peptide Variants from Chia (*S. Hispanica* L.) with Antimicrobial, Antibiofilm, and Antioxidant Potential. *Comput. Biol. Chem.* **2022**, *98*, 107695.

(5) Aguilar-Toalá, J. E.; Vidal-Limon, A.; Liceaga, A. M. Multifunctional Analysis of Chia Seed (*Salvia Hispanica* L.) Bioactive Peptides Using Peptidomics and Molecular Dynamics Simulations Approaches. *Int. J. Mol. Sci.* **2022**, *23*, 7288.

(6) Ozón, B.; Cotabarren, J.; Valicenti, T.; Graciela Parisi, M.; David Obregón, W. Chia Expeller: A Promising Source of Antioxidant, Antihypertensive and Antithrombotic Peptides Produced by Enzymatic Hydrolysis with Alcalase and Flavourzyme. *Food Chem.* **2022**, 380, 132185.

(7) Grancieri, M.; Verediano, T. A.; Sant'Ana, C. T.; de Assis, A.; Toledo, R. L.; de Mejia, E. G.; Martino, H. S. D. Digested Protein from Chia Seed (*Salvia Hispanica* L.) Prevents Obesity and Associated Inflammation of Adipose Tissue in Mice Fed a High-Fat Diet. *PharmaNutrition* **2022**, *21*, 100298.

(8) Cruz-Casas, D. E.; Aguilar, C. N.; Ascacio-Valdés, J. A.; Rodríguez-Herrera, R.; Chávez-González, M. L.; Flores-Gallegos, A. C. Enzymatic Hydrolysis and Microbial Fermentation: The Most Favorable Biotechnological Methods for the Release of Bioactive Peptides. *Food Chem.: Mol. Sci.* **2021**, *3*, 100047.

(9) Ying, X.; Agyei, D.; Udenigwe, C.; Adhikari, B.; Wang, B. Manufacturing of Plant-Based Bioactive Peptides Using Enzymatic Methods to Meet Health and Sustainability Targets of the Sustainable Development Goals. *Front. Sustain. Food Syst.* **2021**, *5*, 1–22.

(10) Han, J.; Zhang, Q.; Luo, W.; Wang, Z.; Pang, Y.; Shen, X. In vitro Digestion of Whole Chia Seeds (Salvia Hispanica L.): Nutrient

Bioaccessibility, Structural and Functional Changes. Int. J. Food Sci. Technol. 2022, 57, 3727–3734.

(11) Agyei, D.; Tsopmo, A.; Udenigwe, C. C. Bioinformatics and Peptidomics Approaches to the Discovery and Analysis of Food-Derived Bioactive Peptides. *Anal. Bioanal. Chem.* **2018**, *410* (15), 3463–3472.

(12) Kartal, C.; Kaplan Türköz, B.; Otles, S. Prediction, Identification and Evaluation of Bioactive Peptides from Tomato Seed Proteins Using *in silico* Approach. *Food Meas.* **2020**, *14*, 1865.

(13) Valenzuela Zamudio, F.; Segura Campos, M. R. Amaranth, Quinoa and Chia Bioactive Peptides: A Comprehensive Review on Three Ancient Grains and Their Potential Role in Management and Prevention of Type 2 Diabetes. *Crit. Rev. Food Sci. Nutr.* **2022**, 62 (10), 2707–2721.

(14) Mardani, M.; Badakne, K.; Farmani, J.; Aluko, R. E. Antioxidant Peptides : Overview of Production, Properties, and Applications in Food Systems. *Compr. Rev. Food Sci. Food Saf.* **2023**, *22*, 46–106.

(15) Santos, H. M.; Coutinho, J. P.; Amorim, F. A. C.; Lôbo, I. P.; Moreira, L. S.; Nascimento, M. M.; de Jesus, R. M. Microwave-Assisted Digestion Using Diluted HNO<sub>3</sub> and  $H_2O_2$  for Macro and Microelements Determination in Guarana Samples by ICP OES. *Food Chem.* **2019**, 273, 159–165.

(16) Montserrat-de-la-Paz, S.; Rivero-Pino, F.; Villanueva, A.; Toscano-Sanchez, R.; Martin, M. E.; Millan, F.; Millan-Linares, M. C. Nutritional composition, ultrastructural characterization, and peptidome profile of antioxidant hemp protein hydrolysates. *Food Biosci.* **2023**, *53*, 102561.

(17) Wang, Y. Y.; Luan, J. J.; Tang, X. H.; Zhu, W. H.; Xu, Y. X.; Bu, Y.; Li, J.; Cui, F.; Li, X. Identification of umami peptides based on virtual screening and molecular docking from Atlantic cod (Gadus morhua). *Food Funct.* **2023**, *14* (3), 1510–1519.

(18) Li, C.; Mora, L.; Toldrá, F. Structure-function relationship of small peptides generated during the ripening of Spanish dry-cured ham: Peptidome, molecular stability and computational modelling. *Food Chem.* **2022**, 375, 131673.

(19) Olsen, T. H.; Yesiltas, B.; Marin, F. I.; Pertseva, M.; García-Moreno, P. J.; Gregersen, S.; Overgaard, M. T.; Jacobsen, C.; Lund, O.; Hansen, E. B.; Marcatili, P. AnOxPePred: Using Deep Learning for the Prediction of Antioxidative Properties of Peptides. *Sci. Rep.* **2020**, *10* (1), 21471.

(20) Manavalan, B.; Basith, S.; Shin, T. H.; Wei, L.; Lee, G. MAHTPred: A Sequence-Based Meta-Predictor for Improving the Prediction of Anti-Hypertensive Peptides Using Effective Feature Representation. *Bioinformatics* **2019**, *35* (16), 2757–2765.

(21) Li, M.; Fan, W.; Xu, Y. Comprehensive Identification of Short and Medium-Sized Peptides from Pixian Broad Bean Paste Protein Hydrolysates Using UPLC-Q-TOF-MS and UHPLC-Q Exactive HF-X. J. Agric. Food Chem. **2022**, 70 (27), 8288–8299.

(22) Kulczyński, B.; Kobus-Cisowska, J.; Taczanowski, M.; Kmiecik, D.; Gramza-Michalowska, A. The Chemical Composition and Nutritional Value of Chia Seeds - Current State of Knowledge. *Nutrients* **2019**, *11* (6), 1242.

(23) Islam, M. S.; Hongxin, W.; Admassu, H.; Noman, A.; Ma, C.; An wei, F. Degree of Hydrolysis, Functional and Antioxidant Properties of Protein Hydrolysates from Grass Turtle (Chinemys Reevesii) as Influenced by Enzymatic Hydrolysis Conditions. *Food Sci. Nutr.* **2021**, *9* (8), 4031–4047.

(24) Tavano, O. L.; Berenguer-Murcia, A.; Secundo, F.; Fernandez-Lafuente, R. Biotechnological Applications of Proteases in Food Technology. *Compr. Rev. Food Sci. Food Saf.* **2018**, *17*, 412–436.

(25) Karaś, M. Influence of Physiological and Chemical Factors on the Absorption of Bioactive Peptides. *Int. J. Food Sci. Technol.* 2019, 54, 1486–1496.

(26) Sun, X.; Udenigwe, C. C. Chemistry and Biofunctional Significance of Bioactive Peptide Interactions with Food and Gut Components. J. Agric. Food Chem. 2020, 68 (46), 12972–12977.

(27) Aluko, R. E. Food Protein-Derived Peptides: Production, Isolation, and Purification, 2nd ed.; Elsevier Ltd., 2017.

(28) Goulart, A. J.; Bassan, J. C.; Barbosa, O. A.; Marques, D. P.; Silveira, C. B.; Santos, A. F.; Garrido, S. S.; Resende, F. A.; Contiero, J.; Monti, R. Transport of Amino Acids from Milk Whey by Caco-2 Cell Monolayer after Hydrolytic Action of Gastrointestinal Enzymes. *Food Res. Int.* **2014**, *63*, 62–70.

(29) Rivero-Pino, F.; Espejo-Carpio, F. J.; Guadix, E. M. Production and Identification of Dipeptidyl Peptidase IV (DPP-IV) Inhibitory Peptides from Discarded Sardine Pilchardus Protein. *Food Chem.* **2020**, 328, 127096.

(30) Millan-Linares, M. C.; Lemus-Conejo, A.; Yust, M. M.; Pedroche, J.; Carrillo-Vico, A.; Millan, F.; Montserrat-de-la-Paz, S. GPETAFLR, a Novel Bioactive Peptide from *Lupinus Angustifolius* L. Protein Hydrolysate, Reduces Osteoclastogenesis. *J. Funct. Foods* **2018**, 47, 299–303.

(31) Mune Mune, M. A.; Minka, S. R.; Henle, T. Investigation on Antioxidant, Angiotensin Converting Enzyme and Dipeptidyl Peptidase IV Inhibitory Activity of Bambara Bean Protein Hydrolysates. *Food Chem.* **2018**, *250*, 162–169.

(32) Aguilar-Toalá, J. E.; Quintanar-Guerrero, D.; Liceaga, A. M.; Zambrano-Zaragoza, M. L. Encapsulation of Bioactive Peptides: A Strategy to Improve the Stability, Protect the Nutraceutical Bioactivity and Support Their Food Applications. *RSC Adv.* **2022**, *12* (11), 6449–6458.

(33) Mooney, C.; Haslam, N. J.; Pollastri, G.; Shields, D. C. Towards the Improved Discovery and Design of Functional Peptides: Common Features of Diverse Classes Permit Generalized Prediction of Bioactivity. *PLoS One* **2012**, *7*, No. e45012.

(34) Mora, L.; González-Rogel, D.; Heres, A.; Toldrá, F. Iberian Dry-Cured Ham as a Potential Source of  $\alpha$ -Glucosidase-Inhibitory Peptides. *J. Funct. Foods* **2020**, *67*, 103840.

(35) Rivero-Pino, F.; Espejo-Carpio, F. J.; Guadix, E. M. Unravelling the  $\alpha$ -Glucosidase Inhibitory Properties of Chickpea Protein by Enzymatic Hydrolysis and *in silico* Analysis. *Food Biosci.* **2021**, *44*, 101328.

(36) Grancieri, M.; Martino, H. S. D.; Gonzalez de Mejia, E. Chia (*Salvia Hispanica* L.) Seed Total Protein and Protein Fractions Digests Reduce Biomarkers of Inflammation and Atherosclerosis in Macrophages In Vitro. *Mol. Nutr. Food Res.* **2019**, *63* (19), 1–15.

(37) Lu, R. R.; Qian, P.; Sun, Z.; Zhou, X. H.; Chen, T. P.; He, J. F.; Zhang, H.; Wu, J. Hempseed Protein Derived Antioxidative Peptides: Purification, Identification and Protection from Hydrogen Peroxide-Induced Apoptosis in PC12 Cells. *Food Chem.* **2010**, *123* (4), 1210– 1218.

(38) Rivero-Pino, F.; Pérez Gálvez, R.; Espejo-Carpio, F. J.; Guadix, E. M. Evaluation of *Tenebrio molitor* protein as a source of peptides for modulating physiological processes. *Food Funct.* **2020**, *11*, 4376–4386.

(39) Peredo-Lovillo, A.; Hernández-Mendoza, A.; Vallejo-Cordoba, B.; Romero-Luna, H. E. Conventional and *in silico* Approaches to Select Promising Food-Derived Bioactive Peptides: A Review. *Food Chem.:* X **2022**, *13*, 100183.

(40) Ryder, K.; Bekhit, A. E. D.; McConnell, M.; Carne, A. Towards Generation of Bioactive Peptides from Meat Industry Waste Proteins: Generation of Peptides Using Commercial Microbial Proteases. *Food Chem.* **2016**, *208*, 42–50.

(41) Alnuaimi, A.; Fisayo Ajayi, F.; Hamdi, M.; Mudgil, P.; Kamal, H.; Yuen Gan, C.; Maqsood, S. A Comparative Analysis of Anti-Lipidemic Potential of Soybean (Glycine Max) Protein Hydrolysates Obtained from Different Ripening Stages: Identification, and Molecular Interaction Mechanisms of Novel Bioactive Peptides. *Food Chem.* **2023**, 402, 134192.

(42) Rahmani-Manglano, N. E.; Jones, N. C.; Hoffmann, S. V.; Guadix, E. M.; Pérez-Gálvez, R.; Guadix, A.; García-Moreno, P. J. Structure of Whey Protein Hydrolysate Used as Emulsifier in Wet and Dried Oil Delivery Systems: Effect of PH and Drying Processing. *Food Chem.* **2022**, *390*, 133169.

(43) Yu, F.; Zhang, Z.; Luo, L.; Zhu, J.; Huang, F.; Yang, Z.; Tang, Y.; Ding, G. Identification and Molecular Docking Study of a Novel Angiotensin-I Converting Enzyme Inhibitory Peptide Derived from

Enzymatic Hydrolysates of Cyclina sinensis. Mar. Drugs 2018, 16 (11), 411 16.

(44) Zarei, M.; Abidin, N. B. Z.; Auwal, S. M.; Chay, S. Y.; Abdul Haiyee, Z.; Md Sikin, A.; Saari, N. Angiotensin Converting Enzyme (ACE)-Peptide Interactions: Inhibition Kinetics, In Silico Molecular Docking and Stability Study of Three Novel Peptides Generated from Palm Kernel Cake Proteins. *Biomolecules* **2019**, *9*, 569.